NCT06754605View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

480

Participants

Timeline

Start Date

February 6, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2027

Conditions
Respiratory Syncytial Virus
Interventions
BIOLOGICAL

SCTV02

Participants will receive a singe dose of SCTV02 on Day 0.

BIOLOGICAL

Placebo

Participants will receive a singe dose of Placebo on Day 0.

Trial Locations (2)

646399

NOT_YET_RECRUITING

Luzhou Center for Disease Control and Prevention, Luzhou

965000

RECRUITING

Hebei Zhongshiyou Central Hospital, Langfang

All Listed Sponsors
lead

Sinocelltech Ltd.

INDUSTRY